Conditions: Psoriasis Melanoma Non-melanoma Skin Cancer
Keywords: psoriasis melanoma non-melanoma skin cancer etanercept Enbrel
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 6
Healthy volunteers: yes

Brief summary:
In psoriasis patients, thick psoriatic plaques can obscure these lesions, and clinicians rely heavily on visual inspection to recognize suspicious or atypical pigmented lesions. However, successful systemic treatment and subsequent clearing of psoriatic plaques may allow clinicians to better evaluate pigmented lesions, thereby increasing the likelihood of early identification and treatment of suspicious lesions such as nonmelanoma skin cancer and malignant melanoma.

Detailed description:
No further description is desired.

Arms:
arm 1: open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks

Interventions: intervention 1: etanercept
Intervention descriptions: intervention 1: Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.

Protocol document: